Brentuximab vedotin and rifampicin

Phase 1Antibody–drug conjugate

Brentuximab vedotin and rifampicin is one of 48 small molecule programs targeting Anaplastic Large Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic Large Cell LymphomaActive, not recruiting

Anaplastic Large Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Anaplastic Large Cell Lymphoma

#DrugCompanyPhaseTrials

Xalkori

PPrism Pharmaceuticals

Approved

4 2

Lorbrena

Gleevec

Trexall

Alnylam Pharmaceuticals

Phase 3

5 5

Cytosar

Teva

Phase 3

4 6

Navelbine

PPierre Fabre Medicament

Ixempra

Adriamycin

GGynecologic Oncology Group

Phase 3

5 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

4 10

Vepesid

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anaplastic Large Cell Lymphoma1 trial

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 1·NCT01950364·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Brentuximab vedotin and rifampicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brentuximab vedotin and rifampicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brentuximab vedotin and rifampicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 1[1]
Company: Takeda

Brentuximab vedotin and rifampicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anaplastic Large Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News